Kingston H G Mills Selected Research

E coli heat-labile enterotoxin

1/2017	Recombinant BCG Expressing LTAK63 Adjuvant induces Superior Protection against Mycobacterium tuberculosis.
5/2011	Escherichia coli heat-labile enterotoxin promotes protective Th17 responses against infection by driving innate IL-1 and IL-23 production.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kingston H G Mills Research Topics

Disease

40	Infections 07/2022 - 01/2002
24	Inflammation (Inflammations) 07/2022 - 05/2004
23	Whooping Cough (Pertussis) 01/2021 - 09/2004
19	Autoimmune Diseases (Autoimmune Disease) 01/2020 - 11/2004
18	Neoplasms (Cancer) 11/2022 - 01/2002
8	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 01/2020 - 07/2006
8	Communicable Diseases (Infectious Diseases) 07/2017 - 01/2002
7	Multiple Sclerosis 12/2017 - 12/2009
6	Alzheimer Disease (Alzheimer's Disease) 12/2017 - 01/2012
4	Colitis 01/2019 - 03/2007
4	Obesity 12/2018 - 06/2009
4	Insulin Resistance 10/2013 - 06/2009
3	Hypersensitivity (Allergy) 01/2020 - 01/2005
3	Tuberculosis (Tuberculoses) 01/2017 - 05/2011
3	Diphtheria 12/2005 - 02/2003
2	Asthma (Bronchial Asthma) 01/2020 - 01/2010
2	Psoriasis (Pustulosis Palmaris et Plantaris) 01/2018 - 09/2012
2	Neuroinflammatory Diseases 12/2017 - 10/2009
2	Malaria 07/2017 - 01/2017
2	Reinfection 01/2016 - 04/2014
2	Bacterial Infections (Bacterial Infection) 11/2015 - 10/2008
2	Type 2 Diabetes Mellitus (MODY) 03/2015 - 10/2010
2	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2014 - 01/2012
2	Experimental Melanoma 03/2012 - 06/2008
1	Clostridium Infections 01/2020
1	Colitis-Associated Neoplasms 01/2019
1	Paralysis (Palsy) 12/2018
1	Bites and Stings (Sting) 11/2018

Drug/Important Bio-Agent (IBA)

30	VaccinesIBA 01/2021 - 02/2003
23	CytokinesIBA 07/2022 - 09/2002
23	Interleukin-17 (Interleukin 17)IBA 07/2022 - 12/2006
10	InflammasomesIBA 10/2019 - 08/2010
10	AntigensIBA 01/2019 - 01/2002
9	Interleukin-1 (Interleukin 1)IBA 04/2014 - 12/2006
8	Interleukin-10 (Interleukin 10)IBA 07/2022 - 09/2004
6	Interleukin-23 (Interleukin 23)IBA 11/2018 - 09/2004
6	Proteins (Proteins, Gene)FDA Link 12/2017 - 03/2002
5	Toll-Like Receptor AgonistsIBA 10/2014 - 03/2008
5	InterleukinsIBA 02/2012 - 01/2002
5	AutoantigensIBA 11/2011 - 11/2004
5	Transforming Growth Factor beta (TGF-beta)IBA 08/2009 - 01/2002
4	Pertussis VaccineIBA 10/2020 - 03/2007
4	Interleukin-18 (Interleukin 18)IBA 01/2019 - 05/2011
4	Fatty Acids (Saturated Fatty Acids)IBA 12/2018 - 06/2009
4	Amyloid (Amyloid Fibrils)IBA 12/2017 - 03/2013
4	Interleukin-6 (Interleukin 6)IBA 06/2011 - 06/2008
3	LigandsIBA 11/2022 - 02/2012
3	Biological ProductsIBA 07/2022 - 07/2017
3	Dextrans (Dextran)FDA Link 01/2019 - 06/2013
3	aluminum sulfate (alum)IBA 01/2019 - 10/2014
3	interleukin-21 (interleukin 21)IBA 01/2018 - 08/2009
3	Immunoglobulin G (IgG)IBA 01/2017 - 09/2004
3	Interleukin-1 Receptors (Interleukin 1 Receptor)IBA 10/2013 - 06/2009
3	Neutralizing AntibodiesIBA 06/2013 - 02/2003
3	Toll-Like Receptors (Toll-Like Receptor)IBA 03/2012 - 08/2011
3	Vaccine AdjuvantsIBA 08/2011 - 03/2008
3	LipopolysaccharidesIBA 12/2009 - 05/2004
2	Immune Checkpoint InhibitorsIBA 11/2022 - 01/2017
2	ChemokinesIBA 11/2022 - 10/2008
2	Sialic Acid Binding Immunoglobulin-like LectinsIBA 09/2021 - 01/2021
2	Acellular VaccinesIBA 01/2020 - 12/2006
2	ML-265IBA 01/2020 - 01/2017
2	Pharmaceutical PreparationsIBA 10/2019 - 05/2011
2	pertactin FDA Link 01/2019 - 01/2002
2	LipidsIBA 12/2018 - 10/2013
2	Insulin (Novolin)FDA Link 12/2018 - 06/2009
2	InterferonsIBA 11/2018 - 08/2011
2	Secretory Immunoglobulin A (SIgA)IBA 11/2018 - 02/2003
2	Interleukin-12 (IL 12)IBA 11/2018 - 09/2004
2	Fingolimod Hydrochloride (FTY720)FDA Link 12/2017 - 01/2017
2	E coli heat-labile enterotoxinIBA 01/2017 - 05/2011
2	AntibodiesIBA 01/2017 - 01/2017
2	Interleukin-5 (Interleukin 5)IBA 01/2016 - 09/2004
2	sodium sulfate (sodium bisulfate)FDA LinkGeneric 02/2015 - 06/2013
2	Virulence Factors (Pathogenicity Factors)IBA 01/2014 - 03/2008
2	Cancer VaccinesIBA 03/2012 - 02/2009
2	Messenger RNA (mRNA)IBA 03/2012 - 07/2006
2	Matrix Metalloproteinases (MMPs)IBA 10/2011 - 08/2003
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 06/2011 - 10/2008
2	Glucose (Dextrose)FDA LinkGeneric 06/2011 - 06/2009
2	ChitosanIBA 12/2005 - 02/2004
1	Interleukin-1beta (Interleukin 1 beta)IBA 11/2022
1	Cisplatin (Platino)FDA LinkGeneric 11/2022
1	Chemokine ReceptorsIBA 01/2020
1	CaspasesIBA 01/2020
1	Dinoprostone (PGE2)FDA Link 01/2020
1	AzoxymethaneIBA 01/2019
1	SodiumIBA 01/2019
1	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 12/2018
1	AdipokinesIBA 12/2018
1	Hormones (Hormone)IBA 12/2018
1	Sirolimus (Rapamycin)FDA Link 12/2018
1	bis(3',5')-cyclic diguanylic acidIBA 11/2018
1	MacrolidesIBA 01/2018
1	Azithromycin (Zithromax)FDA LinkGeneric 01/2018
1	Anti-Bacterial Agents (Antibiotics)IBA 01/2018

Therapy/Procedure

11	Therapeutics 01/2017 - 09/2002
2	Intranasal Administration 11/2018 - 09/2007
2	Immunotherapy 02/2012 - 11/2011
1	Fecal Microbiota Transplantation 01/2020